Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow
Conference Call and Webcast Details:
Date:
Time: 4:30 PM (ET) / 1:30 PM (PT)
US/CANADA Toll-free: (844) 515-9178
International: (614) 999-9313
Conference ID: 4054387
Webcast URL: www.protagonist-inc.com under "Events & Presentations" on the Investors page of the company's website
About
Protagonist Therapeutics is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. Its primary focus is to develop potential first-in-class oral gastrointestinal (GI) restricted targeted therapies that block validated biological pathways currently targeted by marketed injectable antibody drugs. Our lead peptide candidates, PTG-100 and PTG-200, are oral targeted therapy drugs being developed for inflammatory bowel diseases (IBD). The alpha-4-beta-7 integrin antagonist peptide PTG-100 is currently in a Phase 2b clinical trial for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist peptide PTG-200 is currently being studied in a Phase 1 clinical trial in healthy volunteers to support further development in Crohn's disease. Both alpha-4-beta-7 integrin and IL-12/23 pathway blockade are approaches that have been validated through
Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland,
View original content with multimedia:http://www.prnewswire.com/news-releases/protagonist-to-announce-fourth-quarter-and-year-end-2017-financial-results-on-march-7-2018-year-end-update-call-to-follow-300606465.html
SOURCE
Joan Kureczka, Bioscribe, Inc., Tel: +1 415-821-2413, Email: Joan@Bioscribe.com; or For Investors: The Trout Group, Marcy Nanus, Tel: +1 646-378-2927, Email: mnanus@troutgroup.com